海正生材1月26日获融资买入403.25万元，融资余额5456.76万元

Group 1 - The core viewpoint of the news is that Zhejiang Haizheng Biomaterials Co., Ltd. is experiencing a decline in both revenue and net profit, alongside notable changes in shareholder structure and financing activities [1][2]. Group 2 - On January 26, Haizheng Biomaterials' stock fell by 1.45%, with a trading volume of 38.68 million yuan. The financing buy-in amount was 4.03 million yuan, while the financing repayment was 4.27 million yuan, resulting in a net financing buy of -0.24 million yuan [1]. - As of January 26, the total margin trading balance for Haizheng Biomaterials was 54.57 million yuan, accounting for 3.24% of its market capitalization, which is above the 70th percentile of the past year [1]. - The company specializes in the research, production, and sales of polylactic acid, with its main revenue sources being pure polylactic acid (78.55%), modified polylactic acid (20.50%), and others (0.96%) [1]. - As of September 30, the number of shareholders decreased by 10.22% to 6,695, while the average circulating shares per person increased by 17.43% to 18,538 shares [2]. - For the period from January to September 2025, Haizheng Biomaterials reported a revenue of 621 million yuan, a year-on-year decrease of 5.74%, and a net profit attributable to shareholders of 4.91 million yuan, down 85.34% year-on-year [2]. - The company has distributed a total of 42.49 million yuan in dividends since its A-share listing [2]. - Notable changes in institutional holdings include new entries from several funds, with the top ten circulating shareholders now including new investors such as招商均衡优选混合A and招商品质发现混合A [2].